Neurosterix raised $63M in a Series A funding led by Perceptive Xontogeny Venture Fund II to advance allosteric modulator therapeutics for neurological disorders.

Apr 03, 2024•over 1 year ago

Amount Raised

$63 Million

Round Type

series a

New YorkTherapeuticsPharmaceuticalBiotechnologyHealth Care

Investors

Acorn BioventuresPerceptive Life Sciences FundPerceptive Xontogeny Venture Fund Ii

Description

Neurosterix launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.

Company Information

Company

Neurosterix

Location

New York, New York, United States

About

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of patients suffering from neurological disorders. Allosteric modulators increase or decrease the activity of target receptors by binding outside of the “active site” where traditional drugs operate. This approach can improve upon the efficacy and tolerability of existing treatments and potentially address new targets to bring therapeutic innovation to existing or new underserved patient communities. Neurosterix is supported by an industry-leading allosteric modulator drug discovery and development platform. For more information, visit neurosterix.com.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech